Press Room

Webinar - Development of Continuous Process API

Start
Wednesday, April 12, 2017 - 14:00
End
Wednesday, April 12, 2017 - 17:00
Location: online
Webinar - Development of Continuous Process API | Hovione
Speakers
Rudi Oliveira - Chemist, Continuous Manufacturing
Ruth Morais - Engineering, Continuous Manufacturing

Flow chemistry for the manufacturing of active pharmaceutical ingredients (APIs), which has been utilized in numerous industries for many decades, is attracting significant attention from the pharmaceutical industry. The main benefits associated continuous processing are reduced development time and operating costs, greater process safety when employing hazardous chemistries and improved process efficiencies, control and product quality. Hovione are focused on the development and implementation of capabilities for continuous processing. 

So, a practical methodology to perform continuous process development of API’s was built as a systematic workflow which involves several steps: idea screening to identify drivers and objectives, followed by a technical evaluation to select an appropriate technology and identify risks; passing through a process understanding and development phase at laboratory scale to assess the feasibility of converting batch process into a continuous one and ends up with scale-up, engineering studies and industrialization. 

Additionally, this workflow is embedded with a QbD rationale, resorting to mechanistic and statistical modelling to build process understanding and assist scale-up activities. Furthermore, kinetic models can be used along the process lifecycle to assist risk evaluation and process troubleshoot.

Learn more with this webinar, where practical cases that focus on how Hovione apply this workflow are presented.

 

What can you learn from this webinar?

  • Use of kinetic modeling to support continuous process development

  • Lessons learned from converting batch to continuous processes

  • How Hovione used structured workflow to perform continuous process development of APIs

 

Join Hovione's Webinar NOW!

Time Option 1 Time Option 2
register-now
2:00 pm (GMT)

10:00 am (EST)
4:00 pm (GMT)

8:00 am (PST)

11:00 pm (EST)

 

 

 

 

 

You might be also interested in:

Also in the Press Room

See All

Aim to accelerate drug development and production with new technologies. By: Charlie Sternberg Hovione, an international integrated pharmaceutical development and manufacturing organization, and Microinnova Engineering, a leader in continuous process intensification, have partnered to advance the development of multi-purpose, plug-and-play modular equipment for flow chemistry. The companies will work together to test Microinnova’s modular manufacturing equipment, which is designed to offer greater flexibility, easier scalability, enhanced efficiency, and sustainable practices in active ingredient production, in an industrial setting. Together, the companies aim to accelerate process development, facilitate a seamless transition from lab to large-scale manufacturing, and ultimately reduce the time to market for pharmaceutical customers. “This collaboration with Microinnova underscores Hovione’s commitment to innovation in pharmaceutical manufacturing, with flow chemistry playing an important role in our long-term drug substance strategy,” said Dr. Jean-Luc Herbeaux, CEO of Hovione. “This partnership will allow us to shape and validate emerging continuous manufacturing technologies, which can potentially accelerate drug development and production.” Dr. Dirk Kirschneck, Founder and Strategic Director at Microinnova, added, “This partnership reflects our shared vision to deliver modular manufacturing technologies that support pharmaceutical innovation and manufacturing excellence. We are proud to join forces with Hovione to showcase the capabilities of our next-generation modular equipment in a dynamic CDMO environment, demonstrating its versatility for multi-purpose manufacturing.”   Read the full article on ContractPharma.com  

Press Clipping

Hovione, Microinnova Partner to Test Modular Manufacturing Equipment

Sep 24, 2025

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025